Based on the limited available information, VEGF-A-targeted bevacuzimab-IRDye800CW demonstrated tumor visualization; although, it has proven insufficient for accurate tumoral delineation and real-time assessment of the resection margins. This evidence concerns the gene VEGFA and neoplasm.